Patents by Inventor Helene Skjot-Arkil
Helene Skjot-Arkil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9880177Abstract: A method of bioassay for the quantification of biomarkers useful in the diagnosis of fibrosis disease and prognosis of its development, including biomarkers indicative of the risk of developing fibrosis after a chronic injury is provided. In particular, according to the present invention, biomarkers relating to degradation fragments of Collagen type I, III, IV, V, and VI, elastin, C-reactive protein, and proteoglycans including Biglycan, Decorin, Versican, and Perlecan are found to be useful.Type: GrantFiled: March 1, 2017Date of Patent: January 30, 2018Assignee: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Oersnes-Leeming, Natasha Barascuk Michaelsen, Helene Skjot-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis
-
Publication number: 20170176458Abstract: Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a bioflui sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. The protein is collagen type I, collagen type IV, collagen type V, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein.Type: ApplicationFiled: March 1, 2017Publication date: June 22, 2017Applicant: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Oersnes-Leeming, Natasha Barascuk Michaelsen, Helene Skjot-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis
-
Patent number: 9606130Abstract: Provided herein are methods of diagnosis or of quantitation of fibrosis. An immunoassay is conducted to measure neo-epitope containing protein fragments of collagen type III, collagen type I, collagen type IV, collagen type V, or collagen type VI, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein naturally present in a biofluid sample obtained from a patient. An above normal elevation of the measured protein fragments in the patient is associated with the presence or extent of fibrosis.Type: GrantFiled: December 7, 2015Date of Patent: March 28, 2017Assignee: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Oersnes-Leeming, Natasha Barascuk Michaelsen, Helene Skjot-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis
-
Patent number: 9404932Abstract: Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described.Type: GrantFiled: July 20, 2011Date of Patent: August 2, 2016Assignee: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Leeming, Natasha Barascuk, Helene Skjøt-Arkil, Efstathios Vassiliadis
-
Publication number: 20160091502Abstract: Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. The protein is collagen type III, collagen type I, collagen type IV, collagen type V, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein.Type: ApplicationFiled: December 7, 2015Publication date: March 31, 2016Applicant: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Oersnes-Leeming, Natasha Barascuk Michaelsen, Helene Skjot-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis
-
Patent number: 9206464Abstract: Provided herein are methods of diagnosis or of quantitation of fibrosis. An immunoassay is conducted to measure neo-epitope containing protein fragments of collagen type III, collagen type I, collagen type IV, collagen type V, or collagen type VI, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein naturally present in a biofluid sample obtained from a patient. An above normal elevation of the measured protein fragments in the patient is associated with the presence or extent of fibrosis.Type: GrantFiled: March 30, 2010Date of Patent: December 8, 2015Assignee: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Leeming, Natasha Barascuk, Helene Skjot-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis
-
Publication number: 20120045781Abstract: Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described.Type: ApplicationFiled: July 20, 2011Publication date: February 23, 2012Applicant: Nordic Bioscience A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Leeming, Natasha Barascuk, Helene Skjøt-Arkil, Efstathios Vassiliadis
-
Publication number: 20100209940Abstract: Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope, and wherein said protein is collagen type III, collagen type I, collagen type IV, collagen type V, or collagen type VI, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein.Type: ApplicationFiled: March 30, 2010Publication date: August 19, 2010Applicant: NORDIC BIOSCIENCE A/SInventors: Sanne S. Veidal, Morten A. Karsdal, Diana J. Leeming, Natasha Barascuk, Helene Skjøt-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis